Evidence map›Paper›PMID 27387717›Full record

ArticleVeterinary journal (London, England : 1997)2016

Urinary active transforming growth factor β in feline chronic kidney disease.

J S Lawson, H M Syme, C P D Wheeler-Jones, J Elliott

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Veterinary journal (London, England : 1997), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Hemogram-Derived Inflammatory Markers in Cats with Chronic Kidney Disease.Animals : an open access journal from MDPI · 2024
    Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Preliminary study of urinary excretion of liver-type fatty acid-binding protein in a cat model of chronic kidney disease.Canadian journal of veterinary research = Revue canadienne de recherche veterinaire · 2021
    Article
  12. Effects of low-dose meloxicam in cats with chronic kidney disease.Journal of feline medicine and surgery · 2021
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

J S LawsonComparative Biomedical Sciences, The Royal Veterinary College, Royal College Street, London, NW1 0TU, UK. Electronic address: Jlawson@rvc.ac.uk.
H M SymeClinical Sciences and Services, The Royal Veterinary College, Hawkshead Lane, North Mymms, Hatfield, Herts, AL9 7TA, UK.
C P D Wheeler-JonesComparative Biomedical Sciences, The Royal Veterinary College, Royal College Street, London, NW1 0TU, UK.
J ElliottComparative Biomedical Sciences, The Royal Veterinary College, Royal College Street, London, NW1 0TU, UK.
Royal Veterinary College · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The cytokine transforming growth factor beta 1 (TGF-β1) has been widely implicated in the development and progression of renal fibrosis in chronic kidney disease (CKD) in humans and in experimental models. The aims of this study were to assess the association between urinary active TGF-β1 and (a) development of CKD in a cross-sectional study, (b) deterioration of renal function over 1 year in a longitudinal study, and (c) renal histopathological parameters in cats. A human active TGF-β1 ELISA was validated for use in feline urine. Cross-sectional analysis revealed no significant difference in urinary active TGF-β1:creatinine ratio (aTGF-β1:UCr) between groups with differing renal function. Longitudinally, non-azotaemic cats that developed CKD demonstrated a significant (P = 0.028) increase in aTGF-β1:UCr approximately 6 months before the development of azotaemia, which remained elevated (P = 0.046) at diagnosis (approximately 12 months prior, 8.4 pg/mg; approximately 6 months prior, 22.2 pg/mg; at CKD diagnosis, 24.6 pg/mg). In the histopathology study, aTGF-β1:UCr was significantly higher in cats with moderate (P = 0.02) and diffuse (P = 0.005) renal fibrosis than in cats without fibrosis. Cats with moderate renal inflammation had significantly higher urinary active aTGF-β1 concentrations than cats with mild (P = 0.035) or no inflammatory change (P = 0.004). The parameter aTGF-β1:UCr was independently associated with Log urine protein:creatinine ratio in a multivariable analysis of clinicopathological parameters and interstitial fibrosis score in a multivariable analysis of histopathological features. These results suggest that urinary aTGF-β1 reflects the severity of renal pathology. Increases in urinary aTGF-β1 followed longitudinally in individual cats may indicate the development of CKD.

Indexed as

AnimalsBiomarkersCat DiseasesCatsCross-Sectional StudiesFemaleFibrosisKidneyLongitudinal StudiesMaleRenal Insufficiency, ChronicTransforming Growth Factor beta1BiomarkersTGFB1 protein, humanTransforming Growth Factor beta1CatCytokineFibrosisRenalUrine

Identifiers

PMID27387717
PMCPMC4949776
OpenAlexW2255607105

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.